New study tracks how apalutamide works outside of clinical trials

NCT ID NCT06019676

Ongoing Knowledge-focused Sponsor: Royal Marsden NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This observational study follows 170 men with metastatic hormone-sensitive prostate cancer who are taking apalutamide as part of their standard care. Researchers will measure PSA levels and use questionnaires to assess fatigue, thinking skills, and quality of life over two years. The goal is to see how well the drug works in everyday practice, beyond the strict conditions of earlier clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apalutamide
What this could lead to: If successful, this study could provide real-world evidence on how well apalutamide works and its side effects, helping doctors make better treatment decisions for men with metastatic prostate cancer.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It only includes men already choosing apalutamide, which may limit how broadly findings apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)

Contacts and locations

Locations

Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust

Cambridge, CB2 0QQ, United Kingdom
Buckinghamshire Healthcare NHS Trust

Aylesbury, HP21 8AL, United Kingdom
Clatterbrdige Cancer Centre, NHS Foundation Trust

Liverpool, CH63 4JY, United Kingdom
East Lancashire Hospitals NHS Trust

Blackburn, BB2 3HH, United Kingdom
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust

Newcastle, NE7 7DN, United Kingdom
Northern Ireland Cancer Centre, Belfast Health & Social Care Trust

Belfast, BT9 7AB, United Kingdom
South Tyneside and Sunderland NHS Foundation Trust

Newcastle, NE34 0PL, United Kingdom
The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust

Middlesbrough, TS4 3BW, United Kingdom
The Royal Marsden Hospital

Sutton, Surrey, SM2 5PT, United Kingdom
The University Hospital of North Tees

Stockton-on-Tees, TS19 8PE, United Kingdom
University Hospitals of Morecambe Bay NHS Foundation Trust

Lancaster, LA1 4RP, United Kingdom
Velindre Cancer Centre, Velindre University NHS Trust

Cardiff, CF14 2TL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.